7:33 PM
 | 
Sep 11, 2007
 |  BC Extra  |  Company News

Trubion down on trial news

TRBN was off $5.89 (31%) to $13.18 after the company said it thought its TRU-015 would require "additional clinical study" before starting Phase III testing and an analyst downgraded...

Read the full 129 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >